WCN24-2269 MODERATE-SEVERE INTRARENAL ARTERIOSCLEROSIS AND CIRCULATING GDF-15 LEVELS MAY INFLUENCE THE CARDIAC-RENAL PROGNOSIS OF IgAN PATIENTS

WCN24-2269 MODERATE-SEVERE INTRARENAL ARTERIOSCLEROSIS AND CIRCULATING GDF-15 LEVELS MAY INFLUENCE THE CARDIAC-RENAL PROGNOSIS OF IgAN PATIENTS

Saved in:

Bibliographic Details
Main Authors:	Hong Cheng, Zi-wei Wei, Wei-yi Guo, Xiao-yi Xu, Guo-qin Wang, Nan Ye, Li-jun Sun, Hong-rui Dong, Ling-qiang Kong
Format:	Article
Language:	English
Published:	Elsevier 2024-04-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924007253
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

WCN25-799 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS (IA) OF THE PHASE 3 APPLAUSE-IgAN STUDY
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

WCN25-716 EFFECT OF IPTACOPAN ON PROTEINURIA AND COMPLEMENT BIOMARKERS IN IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE PHASE 3 APPLAUSE-IgAN STUDY
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

WCN25-778 AFFINITY study: 1-year results of atrasentan in IgA nephropathy (IgAN)
by: Jonathan Barratt, et al.
Published: (2025-02-01)

WCN25-2522 ORIGIN Extend: A Long-Term Extension Study of Atacicept in IgAN
by: Jonathan Barratt, et al.
Published: (2025-02-01)

WCN25-1585 A Phase 1/2 Trial of Zigakibart in IgA Nephropathy (IgAN)
by: Jonathan Barratt, et al.
Published: (2025-02-01)

WCN25-1084 INTERNATIONAL RISK-PREDICTION TOOL IN IgAN AND THE PROGNOSTIC IMPLICATIONS OF CRESCENTS
by: Beatriz Mendes, et al.
Published: (2025-02-01)

WCN25-797 SAFETY AND EFFICACY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN) WITH BASELINE eGFR 20-<30 mL/MIN: PHASE 3 APPLAUSE-IgAN SUBCOHORT RESULTS
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

Skeletal muscle mitochondrial dysfunction is associated with increased Gdf15 expression and circulating GDF15 levels in aged mice
by: J. Chen, et al.
Published: (2025-03-01)

WCN25-4528 POST TRANSPLANT CRESCENTIC IgAN- FIRST CASE SERIES FROM INDIA
by: NITISH THAKUR, et al.
Published: (2025-02-01)

WCN25-2470 Long-term Results from the ORIGIN Phase 2b Study of Atacicept for the Treatment of IgAN
by: Vivekanand Jha, et al.
Published: (2025-02-01)

WCN24-2352 Improved Proteinuria Reduction with the use of Sparsentan and Targeted Release Budesonide in advanced IgAN
by: Neeharik Mareedu, et al.
Published: (2024-04-01)

2bRAD-M reveals circulating microbiome in chronic antibody-mediated rejection (CAMR) and IgA nephropathy (IgAN) after kidney transplantation
by: Yan-Xin Tao, et al.
Published: (2025-07-01)

WCN25-1884 SPARSENTAN (SPAR) AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE SPARTAN TRIAL
by: Chee Kay Cheung, et al.
Published: (2025-02-01)

WCN24-1506 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY: INTERIM RESULTS FROM THE PHASE 3 APPLAUSE-IgAN STUDY
by: Vlado Perkovic, et al.
Published: (2024-04-01)

WCN24-1774 eGFR DECLINE IN PATIENTS WITH IgAN TREATED WITH NEFECON OR PLACEBO: RESULTS FROM THE 2-YEAR NefIgArd PHASE 3 TRIAL
by: Richard Lafayette, et al.
Published: (2024-04-01)

Association of GDF 15 and Telomere Length of Circulating Leukocytes in Patients with Sleep Apnea
by: Irina M. Madaeva, et al.
Published: (2025-03-01)

WCN25-1898 IMPLICATIONS OF PROTEINURIA REMISSION ON ESTIMATED GLOMERULAR FILTRATION RATE (eGFR) TRAJECTORY IN PATIENTS (Pts) WITH IgA NEPHROPATHY (IgAN) IN PROTECT
by: Bruce Hendry, et al.
Published: (2025-02-01)

WCN24-1776 NEFECON EFFECT ON QUALITY OF LIFE IN PATIENTS WITH IgAN: SF-36 RESULTS FROM THE PHASE 3 NeFIgArd TRIAL
by: Jonathan Barratt, et al.
Published: (2024-04-01)

WCN24-1777 NEFECON TREATMENT PROVIDES KIDNEY BENEFITS FOR PATIENTS WITH IgAN THAT EXTEND TO THOSE WITH LOW LEVELS OF UPCR: A SUB-ANALYSIS OF THE PHASE III NefIgArd TRIAL
by: Jonathan Barratt, et al.
Published: (2024-04-01)

The Role of Progenitor Cells in the Pathogenesis of Arteriosclerosis
by: Yuesheng Zhang, et al.
Published: (2024-09-01)

WCN25-52 EPIDEMIOLOGY OF IMMUNOGLOBULIN A NEPHROPATHY (IgAN) AND OCCURRENCE OF PROTEINURIA IN CHINA: EVIDENCE FROM SYSTEMATIC REVIEW AND META-ANALYSIS
by: Zhaoxin Chen, et al.
Published: (2025-02-01)

WCN25-318 FELZARTAMAB DURABLY REDUCES DISEASE RELEVANT BIOMARKERS THROUGH TARGETING OF CD38+ PLASMA CELLS AND PLASMABLASTS, THE UPSTREAM DRIVERS OF IgA NEPHROPATHY (IgAN)
by: Lisa Kivman, et al.
Published: (2025-02-01)

Significance of intrarenal vascular lesions in Ig A nephropathy prognosis
by: Hyeon Tae Yang, et al.
Published: (2024-10-01)

Burden of corticosteroid therapy in patients with immunoglobulin A nephropathy (IgAN): a systematic literature review
by: Sarah N. Ali, et al.
Published: (2025-05-01)

Editorial: Diagnosis and treatment for arteriosclerosis and thrombosis
by: Yang Liu, et al.
Published: (2025-05-01)

To elucidate the effect of Ruanjian Qingmai granules on arteriosclerosis obliterans from the perspective of cholesterol efflux
by: Chenglin Jia, et al.
Published: (2025-08-01)

GDF-15 as a biomarker for diagnosis and prognosis of lung cancer: a meta-analysis
by: Teng Pan, et al.
Published: (2025-03-01)

Emerging Roles of GDF15 in Metabolic and Cardiovascular Diseases
by: Tian Tian, et al.
Published: (2025-01-01)

WCN24-577 STEROID CONTROVERSIES IN THE TREATMENT OF IGANEPHROPATHY: CLINICAL CASE OF RAPID PROGRESSIVE IGAN
by: Olga Chub
Published: (2024-04-01)

Impact of arteriosclerosis on the functioning of arteriovenous fistula for hemodialysis
by: Stolić Radojica, et al.
Published: (2007-01-01)

Intracranial arteriosclerosis is not associated with cerebral amyloid deposition
by: Anna M. Streiber, et al.
Published: (2024-10-01)

WCN24-847 SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL
by: Jonathan Barratt, et al.
Published: (2024-04-01)

WCN24-752 CONCOMITANT SPARSENTAN AND SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS (SGLT2is) IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN) IN THE PROTECT OPEN-LABEL EXTENSION (OLE)
by: Radko Komers, et al.
Published: (2024-04-01)

Correlation between serum GDF-15 and nutritional state in adults
by: Ahmed Ali, et al.
Published: (2025-07-01)

Plasma GDF-15 concentration is not elevated in open-angle glaucoma.
by: Wouter H G Hubens, et al.
Published: (2021-01-01)

124. ENFERMEDAD MITOCONDRIAL. BIOPSIA MUSCULAR Y GDF15
by: O. Toldos González, et al.
Published: (2024-11-01)

Growth Differentiation Factor-15 (GDF-15) is a Biological Marker in Heart Failure
by: A. M. Alieva, et al.
Published: (2023-01-01)

WCN24-1268 End-Stage Kidney Disease (ESKD) and Chronic Kidney Disease (CKD) Progression among a Hispanic/Latino Population with Primary Immunoglobulin A Nephropathy (IgAN)
by: John Sim, et al.
Published: (2024-04-01)

Single-cell and spatial analyses of the GDF family in tumors, with a focus on the prognostic and biological role of GDF15 in hepatocellular carcinoma
by: Xiaoqian Feng, et al.
Published: (2025-06-01)

Understanding intrarenal backflow: Intrarenal pressure during ureteroscopy and beyond
by: Palle J.S. Osther, et al.
Published: (2024-04-01)